IBI3004 / Innovent Biologics - LARVOL DELTA

A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=106 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: May 2024 ➔ Aug 2024

Enrollment open • Metastases • Trial initiation date • Oncology • Solid Tumor

China News Health Weekly | The leading Chinese medicine company Tasly changed hands, and the chairman of Laobaixing Pharmacy, Xie Zilong, was detained [Google translation] (Eastmoney.com) - "On July 30, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that Innovent Biologics' Class 1 new drug IBI3004 has obtained implicit approval for clinical trials and is intended to be developed to treat solid tumors such as colorectal cancer."

New trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=106 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor